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ABSTRACT 
Objective 
To test the psychometric performance of a modified Disease Activity index for PSoriatic 
Arthritis (DAPSA) using 28 instead of 66 swollen/68 tender joint counts (SJC/TJC). 
 
Methods 
We included PsA patients from the Danish national quality registry DANBIO, divided into 
examination (n=3157 patients,23987 visits) and validation cohorts (n=3154 patients,24160 
visits). We defined DAPSA28=(28TJCxconversion factor1)+(28SJCxconversion factor2)+patient 
global[0-10VAS]+pain[0-10VAS]+CRP[mg/dL]. Identification of the conversion factors was 
performed by Generalized Estimating Equations in the examination cohort and evaluation of 
criterion, correlational and construct validity in the validation cohort. 
 
Results 
We estimated DAPSA28=(28TJCx1.6)+(28SJCx1.6)+patient global[0-10VAS]+pain[0-
10VAS]+CRP[mg/dL]. Criterion validity: DAPSA/DAPSA28 had comparable discriminative 
power expressed as standardized mean difference (DAPSA, 0.90; DAPSA28, 0.93) to 
distinguish between patients in high and low disease activity. Kappa with quadratic 
weighting of DAPSA/DAPSA28 disease activity states was high; 0.92 95%CI (0.92-0.92). 
Standardized response means for DAPSA/DAPSA28 were -0.96/-0.92 for visits after 
bDMARD-initiation. Correlational validity: Baseline DAPSA/DAPSA28 had high correlation 
with DAS28CRP (r=0.87/r=0.93), SDAI (r=0.92/r=0.99),p<0.001. Bland-Altman plot showed 
better agreement between DAPSA/DAPSA28 for low than high disease activity. Construct 
validity: DAPSA/DAPSA28 were similarly correlated to HAQ; r=0.60/0.62, p<0.001. 
DAPSA/DAPSA28 discriminated patients reporting their symptom state as acceptable vs. not 
acceptable equally well: mean(SD) 9.1(8.7)/8.4(8.0) and 24.2(14.9)/22.5(13.8), respectively.  
 
Conclusion 
Our study suggests that data sets with only 28-joint counts available can be used to calculate 
DAPSA28, especially in patients with low disease activity. DAPSA28 showed good criterion, 
correlational and construct validity, and sensitivity to change. Still, our results support that 
66/68 joint count should be performed and the original DAPSA should be preferred in PsA. 
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BACKGROUND 
The Disease Activity index for PSoriatic Arthritis (DAPSA), originally developed for reactive 
arthritis,1 was validated for psoriatic arthritis (PsA) in 2010 and is based on the simple 
summation of visual analogue scales (0-10 cm) of patient’s global and pain assessments, 66 
swollen joint count (66SJC), 68 tender joint count (68TJC) and C-reactive protein (CRP, 
mg/dL).2 These variables had previously been identified in principal component analysis as 
most reflective of PsA disease activity.3 
In 2015 cut-off values for DAPSA remission (≤4), low (≤14), moderate (>14 ≤28) and high 
(>28) disease activity were proposed, as well as debated.4-6 
By virtue of joint involvement in PsA, which often comprises swelling and tenderness of 
distal interphalangeal, ankle and foot joints, the 66/68 joint counts are traditionally used to 
assess PsA patients during clinical examinations. However, many databases and registries 
solely collect 28 joint counts and not the comprehensive 66/68 joint counts, not only in RA 
but also in PsA patients, despite the lack of face validity of reduced joint counts outside of 
RA. In the present study we assessed whether reduced joint counts may be utilised post-hoc 
also for PsA, or if they have to be regarded as insufficient and thus “lost” for that purpose. 
The background for this study was also that 28-joint counts have been found to be 
sufficiently valid in comparison to more comprehensive joint counts in patients with RA.7-9  
Thus, the objective of this study was to compute and test the potential validity of a 
simplified DAPSA score including 28 instead of the original 66/68 joint counts in PsA patients 
from the Danish national quality registry DANBIO. 
 
METHODS 
DANBIO 
DANBIO is a Danish national quality registry established in year 2000 which provides data on 
the disease course of patients with RA, PsA and ankylosing spondylitis, regardless of 
treatment.10 From year 2006 registration of patients treated with biologic DMARDs 
(bDMARDs) has been mandatory. The completeness of DANBIO regarding the overall use of 
bDMARDs in Denmark has been estimated to be ≥92%.10 PsA patients with peripheral 
disease are routinely monitored by 28-joint disease activity score (DAS28; 4 variables, CRP). 
The 66/68 joint counts are optional. Information on subgroups of PsA (e.g. oligoarthritis, 
polyarthritis, arthritis mutilans) is not recorded. Fully anonymized DANBIO data on patients 
with ICD-10 code 07.03A (Psoriatic Arthritis) were collected. The study was approved by the 
DANBIO steering committee, the RKKP (Regionernes Kliniske Kvalitetsudviklingsprogram) as 
well as the data authorities. Patients’ informed consent and research ethical approval are 
not necessary for this kind of study according to Danish law.  
 
Statistical analyses 
Statistical analyses were performed according to a predefined statistical analysis plan. 
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Descriptive statistics were used to summarize patients’ demographic and baseline variables. 
Quantitative results were compared using Mann-Whitney U test or independent t-test as 
appropriate and proportions using Chi-Square test. The cohort was divided into one 
examination and one validation cohort according to odd or even ID numbers.  
We defined: DAPSA28 = (28TJC x conversion factor1) + (28SJC x conversion factor2) + 
patient’s global assessment [0-10 VAS] + patient’s pain assessment [0-10 VAS] + CRP 
[mg/dL]. Identification of the conversion factors was performed by Generalized Estimating 
Equations (GEE, multiple visits per patient) with 68TJC/66SJC as dependent and 28TJC/28SJC 
as independent variables in the examination cohort. All further analyses were performed in 
the validation cohort. 
Evaluation of criterion validity was performed through 1) assessment of Pearson correlation 
between physician’s global assessment and DAPSA/DAPSA28, 2) evaluation of the 
discriminative power of DAPSA/DAPSA28 to distinguish between groups with high (defined 
as starting bDMARD treatment) or low (defined as not starting or changing 
synthetic/biologic DMARD (s/bDMARD) treatment for ≥60 days) disease activity, including 
assessment of standardized mean differences (mean differences divided by pooled SD), 3) 
Agreement between DAPSA/DAPSA28 disease activity categories, including kappa 
coefficients with linear and quadratic weighting, 4) standardized response means (SRMs). 
Evaluation of correlational validity was performed through 1) correlations between changes 
from start of s/bDMARD treatment to follow-up visits in 28SJC and 66SJC, and in 28TJC and 
68TJC, 2) scatterplots to visualize correlations between DAPSA and DAPSA28, 3) correlations 
between simplified disease activity index (SDAI), clinical disease activity index (CDAI), 
DAS28CRP and DAPSA/DAPSA28, 4) Bland-Altman plot11 of DAPSA and DAPSA28. 
Evaluation of construct validity was performed through 1) Comparison of mean (SD) 
DAPSA/DAPSA28 according to the change and state scores/external anchors: a) patient’s 
evaluation of disease activity (much worse, worse, little worse, unchanged, little better, 
better or much better), b) patient’s acceptable symptom state and c) physician’s global 
assessment with a cut-off <10 (0-100 scale), 2) correlations of DAPSA/DAPSA28 with HAQ at 
several points in time and comparison of mean (SD) HAQ levels for patients in different 
DAPSA/DAPSA28 disease activity states. 
We defined the strength of Pearson correlation coefficients as; none: <0.2, low: 0.2-0.3, 
moderate: >0.3- <0.5, substantial: 0.5-0.7 and high: >0.7. Statistical tests were performed 
using SPSS for Windows V.23.0. 
 
RESULTS  
Demographics and baseline disease activity measures were similar in the examination and 
validation cohorts (table 1). 
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Table 1 Demographic characteristics and baseline variables 
 
Examination cohort 
(n=3157 with  
23987 visits) 
Validation cohort 
(n=3154 with  
24160 visits) 
p-value 
Age (years), mean (SD)  52.0 (13.8) 52.0 (13.8) 0.96 
Female, n (%) 1746 (55.3) 1686 (53.5) 0.14 
66 swollen joint count, mean 
(SD)/ median (25th,75th 
percentile) 
2.3 (4.1)/  0 (0,3) 
(n=1449) 
2.4 (4.4)/ 0 (0,3) 
(n=1450) 0.55 
28 swollen joint count, mean 
(SD)/ median (25th,75th 
percentile) 
1.3 (2.5)/ 0 (0,2) 
(n=3157) 
1.3 (2.4)/ 0 (0,2) 
(n=3154) 0.53 
68 tender joint count,  mean 
(SD)/ median (25th,75th 
percentile) 
6.7 (9.2)/ 3 (0,9) 
(n=1510) 
6.8 (9.3)/ 4 (0,9) 
(n=1506) 0.42 
28 tender joint count, mean 
(SD)/ median (25th,75th 
percentile) 
3.4 (5.2)/ 1 (0,5) 
(n=3157) 
3.3 (5.0)/ 1 (0,4) 
(n=3154) 0.45 
Patient’s global, 0-100 VAS 
scale, mean (SD)/ median 
(25th,75th percentile) 
46.4 (29.6)/ 48 (20, 71) 
(n=2732) 
45.9 (29.0)/ 46 (20, 70) 
(n=2728) 0.53 
Evaluator’s global, 0-100 VAS 
scale, mean (SD)/ median 
(25th,75th percentile) 
16.7 (15.8)/ 12 (5, 24) 
(n=2792) 
16.8 (15.6)/12 (5, 24) 
(n=2806) 0.83 
Patient’s pain, 0-100 VAS 
scale, mean (SD)/ median 
(25th,75th percentile) 
41.0 (26.9)/ 38 (19, 63) 
(n=2664) 
40.3 (26.4)/ 37 (18, 61) 
(n=2670) 0.68 
CRP, mg/L, mean (SD)/ 
median (25th,75th percentile) 
8.6 (16.0)/ 4 (2, 9) 
(n=2780) 
8.4 (13.0)/ 4 (2, 10)  
(n=2754) 0.73 
SDAI, mean (SD)/ median 
(25th,75th percentile) 
11.9 (9.9)/ 9.4 (4.5, 
16.3) (n=2200) 
11.5 (9.7)/ 9 (2, 16)  
(n=2189) 0.22 
CDAI, mean (SD)/ median 
(25th,75th percentile) 
11.0 (9.5)/ 8.7 (4.0, 
15.3) (n=2427) 
10.7 (9.2)/ 8.3 (4.0, 
14.9) (n=2436) 0.33 
DAS28CRP, mean (SD)/ 
median (25th,75th percentile) 
3.1 (1.3)/ 3.0 (2.1, 4.0) 
(n=2483) 
3.1 (1.3)/ 2.9 (2.1, 4.0) 
(n=2455) 0.16 
HAQ, mean (SD)/ median 
(25th,75th percentile) 
0.7 (0.6)/ 0.6 (0.1, 1.1) 
(n=2610) 
0.7 (0.6)/ 0.6 (0.1, 1.0) 
(n=2593) 0.30 
CDAI, clinical disease activity index; CRP, C-reactive protein; DAS28CRP, 28-joint disease activity score 
with CRP; HAQ, Health Assessment Questionnaire; SDAI, simplified disease activity index 
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Transformation to DAPSA28 
By means of GEE we estimated a conversion factor of 1.6 for both TJC 95% CI (1.6-1.7) [8179 
visits included] and for SJC 95% CI (1.5-1.6) [7701 visits included], leading to:  
DAPSA28 = (28TJC x 1.6) + (28SJC x 1.6) + patient’s global assessment [0-10 VAS] + patient’s 
pain assessment [0-10 VAS] + CRP [mg/dL] 
DAPSA and DAPSA28 scores were similar in the examination (n=1949 patients with 5995 
visits) vs. validation cohorts (1975 patients with 6421 visits); Mean (SD)/median (25th-75th 
percentiles) DAPSA: 16.4 (14.5)/12.9 (5.6-22.9) vs. 16.4 (14.5)/13.0 (5.8-22.2), p=0.90; 
DAPSA28: 14.9 (13.7)/11.5 (5.1-20.2) vs. 14.9 (13.3)/11.7 (5.2-20.0), p=0.99, respectively. 
All further analyses were performed in the validation cohort.  
Boxplot showed similar medians (25th-75th percentiles), but some more extreme values for 
DAPSA (supplementary figure S1). 
 
Criterion validity 
Physician’s global assessment and DAPSA/DAPSA28 were overall substantially and similarly 
correlated (r=0.63/r=0.61), p<0.001.  
DAPSA and DAPSA28 had comparable discriminative power, expressed as standardized mean 
difference, to distinguish between patients in high and low disease activity (table 2). 
 
Table 2 Discriminative power to distinguish between patients in high and low disease activity 
 Patients starting 
bDMARD 
treatment 
Patients not starting or 
changing s/bDMARD 
treatment for ≥60 days  
Standardized 
mean 
difference* 
Number of visits/ patients 391/ 290 1946/ 774 
DAPSA, mean (SD)/  
median (25th,75th percentile) 
29.1 (17.4)/  
26.1 (18.0, 37.5)  
15.1 (13.7)/  
12.1 (5.1, 20.4)  0.90 
DAPSA28, mean (SD)/  
median (25th,75th percentile) 
26.9 (15.7)/  
24.5 (16.1, 34.4)  
13.8 (12.5)/  
10.9 (4.6, 18.7)  0.93 
*Standardized mean difference = mean of DAPSA or DAPSA28 in patients starting bDMARD 
subtracted by the mean of DAPSA or DAPSA28 in patients not starting or changing 
s/bDMARD) divided by pooled SD of both treatment groups. 
 
Agreements between DAPSA and DAPSA28 disease activity states,4 using same cut-offs for 
DAPSA28 as DAPSA, were best for patients in remission and low disease activity (table 3). 
DAPSA and DAPSA28 disease activity states were in agreement in 5520 of 6421 (86%) visits, 
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had one grade difference in 887 of 6421 (13.8%) visits and two grade difference in 18 (0.2%) 
visits. 
 
Table 3 Agreement between DAPSA and DAPSA28 disease activity states 
 DAPSA (n=6421) 
DAPSA28 
(n=6421) 
 
Remission; 
DAPSA≤4 
(n=1153) 
Low disease 
activity; 
DAPSA>4 and 
≤14 
(n=2265) 
Moderate 
disease 
activity; 
DAPSA>14 
and ≤28 
(n=1938) 
High disease 
activity; 
DAPSA>28 
(n=1065) 
Remission; 
DAPSA28≤4 
(n=1265) 
1135  
(98.4%)/ 
(89.7%) 
126  
(5.6%)/ 
(10%) 
4  
(0.2%)/  
(0.3%) 
0  
(0%)/  
(0%) 
Low disease 
activity; 
DAPSA28>4 
and≤14 
(n=2450) 
18  
(1.6%)/  
(0.7%) 
2073  
(91.5%)/ 
(84.6%) 
345  
(17.8%)/ 
(14.1%) 
14  
(1.3%)/  
(0.6%) 
Moderate 
disease 
activity; 
DAPSA28>14 
and ≤28 
(n=1823) 
0  
(0%)/ 
(0%) 
66  
(2.9%)/  
(3.6%) 
1509  
(77.9%)/ 
(82.8%) 
248  
(23.3%)/ 
(13.6%) 
High disease 
activity; 
DAPSA28>28 
(n=883) 
0  
(0%)/ 
(0%) 
0  
(0%)/ 
 0%) 
80  
(4.1%)/  
(9.1%) 
803  
(75.4%)/ 
(90.9%) 
n (%) within DAPSA disease activity states/ (%) within DAPSA28 disease activity states 
 
Kappa with linear/ quadratic weighting between DAPSA/DAPSA28 disease activity states was 
0.87, 95% CI (0.86-0.87)/ 0.92 95% CI (0.92-0.92) indicating very good agreement. However, 
table 3 indicates that the agreement differed according to disease activity states. Kappa with 
linear/quadratic weighting between DAPSA/DAPSA28 remission was 0.93 (0.91-0.94)/ 0.93 
(0.92-0.94). 
SRM for very first follow-up visit after start of bDMARD was -0.79 for DAPSA and -0.74 for 
DAPSA28 (n=232). SRM for first follow-up visit with available SRM value after start of 
bDMARD was -0.96 for DAPSA and -0.92 for DAPSA28 (n=572). 
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Correlational validity 
Correlations were high between differences in 28SJC and 66SJC (r=0.84, p<0.001 (n=5758)) 
and between 28TJC and 68TJC (r=0.85, p<0.001 (n=6215)) from start of s/bDMARD 
treatment to follow-up visits. 
Scatterplots showed high correlation between DAPSA and DAPSA28 with higher spread for 
higher disease activity levels and more scores in the upper half (figure 1). Scatterplots of 
baseline DAPSA vs. DAPSA28 stratified according to DAPSA disease activity states showed 
high correlation for patients in remission, low and high disease activity and substantial 
correlation for patients in moderate disease activity (supplementary figure S2a-d). 
DAPSA/DAPSA28 had both high correlations with DAS28CRP, SDAI and CDAI at baseline, as 
well as for all registered visits (table 4).  
 
 Table 4 Correlational validity; Pearson correlations at baseline and of all visits 
Baseline/ All visits (grey background) 
 DAPSA DAPSA28 DAS28CRP SDAI CDAI 
DAPSA 1 
0.93* 
(n=1033) 
0.87* 
(n=1033) 
0.92* 
(n=947) 
0.92* 
(n=947) 
DAPSA28 
0.94*  
(n=6421) 1 
0.93* 
(n=2399) 
0.99* 
(n=2148) 
0.99* 
(n=2148) 
DAS28CRP 
0.89* 
 (n=6421) 
0.94* 
(n=20406) 1 
0.94* 
(n=2189) 
0.92* 
(n=2189) 
SDAI 
0.94* 
(n=5888) 
0.99* 
 (n=18565) 
0.94* 
(n=18819) 1 
0.99* 
(n=2189) 
CDAI 
0.94* 
(n=5888) 
0.99* 
(n=18565) 
0.92* 
(n=18819) 
0.99* 
(n=18819) 1 
*p<0.001 (p found by GEE when multiple registrations per patient) 
 
Bland Altman plots showed better agreement between DAPSA and DAPSA28 for low than 
high disease activity levels (figure 2).   
The differences between DAPSA and DAPSA28 increased with an increasing average of 
DAPSA and DAPSA28.11  This difference between DAPSA and DAPSA28 was skewed and log 
transformation (which is the only transformation recommended by Bland and Altman for 
this plot) did not improve the skewness, hence limits of agreement are not given as they 
would be invalid.11  
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Construct validity 
DAPSA/DAPSA28 were both substantially correlated to HAQ; all visits with DAPSA (n=6204) 
r=0.60/0.62; baseline visits with DAPSA (n=994) r=0.53/r=0.56; starting bDMARD (n=387) 
r=0.55/r=0.59; not starting bDMARD (n=5817) r=0.59/r=0.61, respectively, all p<0.001.  
Mean (SD) HAQ was similar for different DAPSA vs. DAPSA28 categories; remission, 0.2 (0.3)/ 
0.2 (0.3); low disease activity 0.6 (0.5)/ 0.6 (0.5); moderate disease activity 1.0 (0.6)/ 1.1 
(0.6); high disease activity, 1.5 (0.6)/ 1.5 (0.6), respectively. 
Mean (SD) DAPSA and DAPSA28 were comparable for different change and state scores used 
as external anchors, but mean values of DAPSA were consistently higher than for DAPSA28 
(supplementary table S1). 
 
DISCUSSION 
For full assessment of disease activity in PsA there is general agreement about the need to 
assess a full joint count with 68 tender and 66 swollen joints. However, many databases and 
registries only collect 28 joint counts. We used the Danish national quality registry DANBIO 
to explore psychometric performance of a modified DAPSA based on 28 rather than 66/68 
joint counts.  
DAPSA28 showed overall good criterion, correlational and construct validity as well as 
sensitivity to change, but the agreement between DAPSA and DAPSA28 was better for low 
than high disease activity levels. Psychometric performance was also poorer in patients with 
moderate and high disease activity.  
Most patients were classified as having the same disease activity levels, regardless of the use 
of DAPSA or DAPSA28. When discrepancies occurred, these were moderate in magnitude 
and more frequent for patients in high disease activity. Kappa with quadratic weighting was 
high, indicating very good agreement between DAPSA and DAPSA28.  
Correlational validity was good, including high correlations between DAPSA/DAPSA28 and 
DAS28, SDAI and CDAI. All these scores are joint focused and include many of the same 
variables. DAS28 has been validated for use in PsA in clinical trials of biologic therapies and 
SDAI in an observational study on PsA patients.12-14 Of note, longitudinal observational 
studies on PsA patients comparing the performance of DAPSA, DAS28, SDAI and CDAI are 
lacking in the current literature. 
The main objection against the use of DAPSA28 in PsA is the 28 joint counts. It is 
undisputable that a full joint count is preferable to the 28 joint counts in PsA. However, as 
previously mentioned, in many registries and real life observational studies a full joint count 
is not available.   
Further general objections against DAPSA, as well as DAPSA28, are the need for assessment 
of multiple domains in PsA.5 6 However, we believe that in addition to the more extensive 
composite scores of disease activity in PsA like PASDAS15 or CPDAI15, there may be a need for 
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more feasible composite scores like DAPSA/DAPSA28. This issue is under constant debate4-6 
15 and a task force has recently recommended DAPSA for use in PsA.15  
To our knowledge DAPSA28 is the first 28 joint disease activity score developed and 
validated in PsA. It is easy to calculate and may pose an important substitute to DAS28, 
which probably is the mostly used 28-joint composite score in PsA, even if originally 
developed for RA.16 Still, we do not recommend the use of DAPSA28 in clinical practice, as 
the 66/68 joint counts should be used in PsA whenever feasible. Of note, none of the joint 
counts distinguishes between the potentially different clinical relevance of which joints 
being affected. 
The psychometric performance of DAPSA28 in patients with moderate and high disease 
activity was not as good as in patients in remission or with low disease activity. This 
observation may not be surprising since the distal interphalangeal joints and foot joints may 
be assumed to be more frequently inflamed in patients with increasingly overall 
inflammatory activity.  
Limitations of the study include non-standardized times of visits (observational database) as 
well as lack of radiographic data, which could have been useful for additional criterion 
validation. The results may be influenced by choice of study population, as patients in e.g. 
low-income countries may have higher disease activity and different cultural background, 
which possibly might influence the identification of conversion factors. The major strength of 
the study is the large study population from the national Danish longitudinal observational 
database DANBIO, including large numbers of patients with 66/68 joint counts and extensive 
clinical data, as well as patients with both early and established disease. 
In conclusion, we recommend that the original DAPSA should be preferred and that 66/68 
joint counts should be performed in patients with PsA to compute DAPSA. However, our 
study suggests that data sets with only 28-joint counts available can be used to calculate a 
modified DAPSA28, as a valid tool for database or outcomes research in the field of PsA, 
especially in patients with low disease activity. 
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Supplementary figure S1 Boxplot of DAPSA and DAPSA28 (all visits, n=6421) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S2a Scatterplot of baseline DAPSA and DAPSA28 for patients in                
DAPSA remission (n=141) 
 
 
Supplementary Figure S2b Scatterplot of baseline DAPSA and DAPSA28 for patients                
in DAPSA low disease activity (n=342)
 
r=0.95, p<0.001 
r=0.83, p<0.001 
Supplementary Figure S2c Scatterplot of baseline DAPSA and DAPSA28 for patients in DAPSA 
moderate disease activity (n=327) 
 
 
 
Supplementary Figure S2d Scatterplot of baseline DAPSA and DAPSA28 for patients in 
DAPSA high disease activity (n=223) 
 
r=0.57, p<0.001 
r=0.73, p<0.001 
Supplementary table S1 Construct validity, External anchors 
  DAPSA 
mean (SD) 
DAPSA28 
mean (SD) 
Patient’s evaluation 
of disease activity 
since last visit 
(n=1485) 
Much worse (n=71) 34.0 (13.4) 30.3 (11.6) 
Worse (n=237) 24.1 (12.5) 22.7 (12.4) 
Little worse (n=328) 18.2 (15.2) 16.4 (12.9) 
Unchanged (n=566) 12.8 (13.2) 12.0 (12.3) 
Little better (n=146) 12.6 (10.1) 11.7 (9.7) 
Better (n=99) 7.3 (6.7) 6.8 (6.8) 
Much better (n=38) 4.6 (5.9) 3.6 (4.5) 
Patient’s acceptable 
symptom state 
(n=2185) 
Acceptable (n=1140) 9.1 (8.7) 8.4 (8.0) 
Not acceptable (n=1045) 24.2 (14.9) 22.5 (13.8) 
Physician’s global 
assessment (n=5888) 
<10 (0-100 scale) (n=3184) 9.4 (8.3) 8.8 (7.9) 
≥10 (0-100 scale) (n=2704) 24.6 (16.0) 22.1 (14.9) 
 
 
